Panel Discussion: Digital Heath Apps in Clinical Trials: Ready for Prime Time?

Tuesday, March 12, 2024

10:54 AM – 11:32 AM ET

Panel Moderator(s)

Jodi J. Akin, MS

Founder
Hawthorne Effect, Inc.
Alamo, California, United States

Disclosure information not submitted.
Joaquin E. Cigarroa, MD

Head of the Division of Cardiovascular Medicine
OHSU Knight Cardiovascular Institute
Portland, Oregon, United States

No relationships to disclose

Panel Discussant(s)

SB

Stephen Browning, BSE

Assistant Division Director, Hemodynamic and Heart Failure Diagnostic Devices
FDA/CDRH
Silver Spring, Maryland, United States

Disclosure(s): No financial relationships to disclose
Mona Advani, M.Sc., MBA

Principal Regulatory Consultant
CardioMed Device Consultants
HERNDON, Virginia, United States

Disclosure(s): No financial relationships to disclose
C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Beren Therapeutics: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); BOEHRINGER INGELHEIM IT.SpA.: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); Esperion: Consultant (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Consultant (Ongoing), Shareholder (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); New Amsterdam Pharma: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Samsung: Consultant (Ongoing); SCAD Alliance: Consultant (Ongoing); SCAI: Consultant (Ongoing); SFJ: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)